Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Individual Assignment of Adult Diffuse Gliomas into the EM/PM Molecular Subtypes Using a TaqMan Low-Density Array.

Li J, Xue Y, Wenger A, Sun Y, Wang Z, Zhang CB, Zhang Y, Fekete Rydenhag B, Bertil Rydenhag B, Jakola AS, Jiang T, Carén H, Fan X.

Clin Cancer Res. 2019 Sep 3. pii: clincanres.0299.2019. doi: 10.1158/1078-0432.CCR-19-0299. [Epub ahead of print]

PMID:
31481507
2.

A glioma classification scheme based on coexpression modules of EGFR and PDGFRA.

Sun Y, Zhang W, Chen D, Lv Y, Zheng J, Lilljebjörn H, Ran L, Bao Z, Soneson C, Sjögren HO, Salford LG, Ji J, French PJ, Fioretos T, Jiang T, Fan X.

Proc Natl Acad Sci U S A. 2014 Mar 4;111(9):3538-43. doi: 10.1073/pnas.1313814111. Epub 2014 Feb 18.

3.

Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.

Leu K, Ott GA, Lai A, Nghiemphu PL, Pope WB, Yong WH, Liau LM, Cloughesy TF, Ellingson BM.

J Neurooncol. 2017 Aug;134(1):177-188. doi: 10.1007/s11060-017-2506-9. Epub 2017 May 25.

4.

PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.

Draaisma K, Wijnenga MM, Weenink B, Gao Y, Smid M, Robe P, van den Bent MJ, French PJ.

Acta Neuropathol Commun. 2015 Dec 23;3:88. doi: 10.1186/s40478-015-0265-4.

5.

DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.

Paul Y, Mondal B, Patil V, Somasundaram K.

Clin Epigenetics. 2017 Apr 4;9:32. doi: 10.1186/s13148-017-0331-9. eCollection 2017.

6.

Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.

Weller M, Weber RG, Willscher E, Riehmer V, Hentschel B, Kreuz M, Felsberg J, Beyer U, Löffler-Wirth H, Kaulich K, Steinbach JP, Hartmann C, Gramatzki D, Schramm J, Westphal M, Schackert G, Simon M, Martens T, Boström J, Hagel C, Sabel M, Krex D, Tonn JC, Wick W, Noell S, Schlegel U, Radlwimmer B, Pietsch T, Loeffler M, von Deimling A, Binder H, Reifenberger G.

Acta Neuropathol. 2015 May;129(5):679-93. doi: 10.1007/s00401-015-1409-0. Epub 2015 Mar 18.

7.

Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma.

Hu X, Martinez-Ledesma E, Zheng S, Kim H, Barthel F, Jiang T, Hess KR, Verhaak RGW.

Neuro Oncol. 2017 Jun 1;19(6):786-795. doi: 10.1093/neuonc/now285.

8.

DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.

Cohen A, Sato M, Aldape K, Mason CC, Alfaro-Munoz K, Heathcock L, South ST, Abegglen LM, Schiffman JD, Colman H.

Acta Neuropathol Commun. 2015 Jun 20;3:34. doi: 10.1186/s40478-015-0213-3.

9.

Machine Learning-Based Radiomics for Molecular Subtyping of Gliomas.

Lu CF, Hsu FT, Hsieh KL, Kao YJ, Cheng SJ, Hsu JB, Tsai PH, Chen RJ, Huang CC, Yen Y, Chen CY.

Clin Cancer Res. 2018 Sep 15;24(18):4429-4436. doi: 10.1158/1078-0432.CCR-17-3445. Epub 2018 May 22.

10.

Molecular genetics of adult grade II gliomas: towards a comprehensive tumor classification system.

Figarella-Branger D, Bouvier C, de Paula AM, Mokhtari K, Colin C, Loundou A, Chinot O, Metellus P.

J Neurooncol. 2012 Nov;110(2):205-13. doi: 10.1007/s11060-012-0953-x. Epub 2012 Aug 14.

PMID:
22890969
11.

Identification of a Good-Prognosis IDH-Mutant-Like Population of Patients with Diffuse Gliomas.

Wang Z, Liu X, Wang Z, Bao Z, Zhang W, Zhang C, Jiang T.

Curr Mol Med. 2018 Mar 9;17(7):518-526. doi: 10.2174/1566524018666180212151429.

PMID:
29437008
12.

Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p/19q status in diffuse low- and high-grade gliomas.

Zhou H, Chang K, Bai HX, Xiao B, Su C, Bi WL, Zhang PJ, Senders JT, Vallières M, Kavouridis VK, Boaro A, Arnaout O, Yang L, Huang RY.

J Neurooncol. 2019 Apr;142(2):299-307. doi: 10.1007/s11060-019-03096-0. Epub 2019 Jan 19.

13.

PCR-Based Simple Subgrouping Is Validated for Classification of Gliomas and Defines Negative Prognostic Copy Number Aberrations in IDH Mutant Gliomas.

Nakae S, Sasaki H, Hayashi S, Hattori N, Kumon M, Nishiyama Y, Adachi K, Nagahisa S, Hayashi T, Inamasu J, Abe M, Hasegawa M, Hirose Y.

PLoS One. 2015 Nov 11;10(11):e0142750. doi: 10.1371/journal.pone.0142750. eCollection 2015.

14.

Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma.

Chai RC, Zhang KN, Chang YZ, Wu F, Liu YQ, Zhao Z, Wang KY, Chang YH, Jiang T, Wang YZ.

Carcinogenesis. 2019 Jun 3. pii: bgz102. doi: 10.1093/carcin/bgz102. [Epub ahead of print]

PMID:
31157866
15.

Histomolecular classification of adult diffuse gliomas: the diagnostic value of immunohistochemical markers.

Figarella-Branger D, Maues de Paula A, Colin C, Bouvier C.

Rev Neurol (Paris). 2011 Oct;167(10):683-90. doi: 10.1016/j.neurol.2011.07.006. Epub 2011 Sep 1. Review.

PMID:
21889777
16.

Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas.

Sabha N, Knobbe CB, Maganti M, Al Omar S, Bernstein M, Cairns R, Çako B, von Deimling A, Capper D, Mak TW, Kiehl TR, Carvalho P, Garrett E, Perry A, Zadeh G, Guha A, Sidney Croul.

Neuro Oncol. 2014 Jul;16(7):914-23.

17.

Chromosome 17p Homodisomy Is Associated With Better Outcome in 1p19q Non-Codeleted and IDH-Mutated Gliomas.

Labussière M, Rahimian A, Giry M, Boisselier B, Schmitt Y, Polivka M, Mokhtari K, Delattre JY, Idbaih A, Labreche K, Alentorn A, Sanson M.

Oncologist. 2016 Sep;21(9):1131-5. doi: 10.1634/theoncologist.2016-0003. Epub 2016 Jul 8.

18.

IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas.

Olar A, Wani KM, Alfaro-Munoz KD, Heathcock LE, van Thuijl HF, Gilbert MR, Armstrong TS, Sulman EP, Cahill DP, Vera-Bolanos E, Yuan Y, Reijneveld JC, Ylstra B, Wesseling P, Aldape KD.

Acta Neuropathol. 2015 Apr;129(4):585-96. doi: 10.1007/s00401-015-1398-z. Epub 2015 Feb 21.

19.

Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery.

Cimino PJ, Zager M, McFerrin L, Wirsching HG, Bolouri H, Hentschel B, von Deimling A, Jones D, Reifenberger G, Weller M, Holland EC.

Acta Neuropathol Commun. 2017 May 22;5(1):39. doi: 10.1186/s40478-017-0443-7.

20.

Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas.

Yang P, Cai J, Yan W, Zhang W, Wang Y, Chen B, Li G, Li S, Wu C, Yao K, Li W, Peng X, You Y, Chen L, Jiang C, Qiu X, Jiang T; CGGA project.

Neuro Oncol. 2016 Aug;18(8):1099-108. doi: 10.1093/neuonc/now021. Epub 2016 Mar 7.

Supplemental Content

Support Center